Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does selectivity matter?

J F Deakin1

  • 1University Department of Psychiatry, Manchester Royal Infirmary, UK.

International Clinical Psychopharmacology
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Selective serotonin reuptake inhibitors (SSRIs) offer greater efficacy for conditions like OCD and panic disorder compared to noradrenaline reuptake inhibitors (NARIs). While combined inhibition may enhance effects, SSRIs provide a safer profile with reversible side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls.

Molecular psychiatry·2017
Same author

5 -HT, antidepressant drugs and the psychosocial origins of depression.

Journal of psychopharmacology (Oxford, England)·2012
Same author

5-HT drugs in anxiety and panic.

Journal of psychopharmacology (Oxford, England)·2012
Same author

The psychopharmacology of social communication and its disorders: November 1992, London.

Journal of psychopharmacology (Oxford, England)·2012
Same author

A review of clinical efficacy of 5-HT 1A agonists in anxiety and depression.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Annual Meeting, York, England, 22 July 1991: Latent inhibition and other paradigms as models of schizophrenic dysfunction.

Journal of psychopharmacology (Oxford, England)·2012

Area of Science:

  • Pharmacology
  • Neuroscience
  • Drug Development

Background:

  • Drug development aims to maximize efficacy while minimizing side effects and toxicity.
  • Selective serotonin reuptake inhibitors (SSRIs) and noradrenaline reuptake inhibitors (NARIs) are key antidepressant classes.
  • Understanding drug selectivity is crucial for therapeutic outcomes.

Purpose of the Study:

  • To compare the efficacy and safety of SSRIs versus NARIs in treating specific psychiatric disorders.
  • To explore the impact of combined serotonin and noradrenaline reuptake inhibition.
  • To evaluate the role of drug selectivity in therapeutic tolerability and safety.

Main Methods:

  • Comparative analysis of SSRIs and NARIs based on existing clinical evidence.
  • Review of pharmacological properties and side effect profiles.

Related Experiment Videos

  • Assessment of safety data, including overdose toxicity.

    • Main Results:

    • SSRIs demonstrate superior efficacy over NARIs for obsessive-compulsive disorder and panic disorder.
    • Obsessive features in depression predict positive response to SSRIs.
    • Combined inhibition may offer slight efficacy gains, but older non-selective agents carry higher overdose risks.
    • SSRIs possess a more favorable safety profile, with generally reversible side effects.

    Conclusions:

    • Drug selectivity for specific neurotransmitter transporters is critical for both efficacy and safety.
    • SSRIs represent a safer and often more effective treatment option compared to NARIs and older non-selective antidepressants.
    • Patient tolerability and reduced toxicity are key advantages of selective antidepressant agents.